In patients with recurrent platinum-resistant/-refractory ovarian cancer, treatment with botensilimab (Agenus), a novel multifunctional CTLA-4 (cytotoxic T-lymphocyte–associated antigen 4) antibody, plus balstilimab (Agenus), a PD-1 (programmed death-1) antibody, yielded a 33% overall response rate (ORR). Results from the expanded phase 1b trial were presented in an oral plenary session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer (abstract 2).
APRIL 26, 2023